Actos Recall | Actos Bladder Cancer

25 Plaintiffs Allege Actos Bladder Cancer in Illinois Lawsuit

Shay Morrigan | December 19th, 2011

In a new lawsuit filed December 8, 2011 in the circuit court of Cook County, Illinois, 25 plaintiffs from numerous states allege Actos bladder cancer and seek compensation from manufacturer Takeda Pharmaceuticals. The plaintiffs each ingested the diabetes drug pioglitazone (brand name Actos)—which was the target of a recent Actos recall in France—or similar drugs like Actoplus Met, Actoplus Met XR, or Duetact.

Multiple plaintiffs allege Actos bladder cancer

Each of the plaintiffs involved in this Actos lawsuit ingested the drug (or a related medication) over a prolonged period of time as prescribed by a physician to treat diabetes, and each contracted Actos bladder cancer. The 25 Actos lawsuit plaintiffs are seeking compensatory damages to cover the costs related to their Actos bladder cancer, and general damages for the wrongful conduct of the defendants.

On June 15, 2011, nearly at the same time as the French Actos recall, the FDA released a warning concerning Actos bladder cancer, as studies had indicated that those on the medication for longer than a year had a higher risk of the disease.

Actos recall so far limited to France

After reviewing data from the French National Health Insurance Plan, which showed an increased risk of Actos bladder cancer in those taking pioglitazone compared to other diabetes medications, the French Medicines Agency spurred the Actos recall by implementing a suspension of sales on June 9, 2011.

Takeda followed up with a voluntary Actos recall on July 12, 2011. After reviewing the results of the French study, Germany followed suit, though instead of an Actos recall, they informed physicians to stop prescribing the medication to new patients.

In the wake of the Actos recall in France, many speculated that Europe as a whole may follow suit, but on October 21, 2011, the European Medicines Agency stated they would not recommend an Actos recall. They did, however, recommend that Actos be used only when other diabetes treatments fail.

Actos lawsuit claims Takeda failed to warn of Actos bladder cancer

Though so far the U.S. has not implemented an Actos recall, plaintiffs alleging Actos bladder cancer continue to come forward to file an Actos lawsuit. In this case, plaintiffs allege that the risks of Actos outweigh the benefits, and that manufacturer Takeda concealed knowledge that plaintiffs were at risk of Actos bladder cancer.

FDA warns of Actos bladder cancer

In its June safety warning, the FDA stopped short of an Actos recall, but did state that, “use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer.” Exposure to the drug for longer than 12 months was associated with a 40 percent increase risk of Actos bladder cancer.